S18:Risk of NAFLD based on available serum SHBG measurement following exclusion of participants with PCOS/PCO codes (n= 38,784)

|  |  |  |  |
| --- | --- | --- | --- |
| **Covariate** | **Hazard ratio** |  | **P Value** |
| **95% CI** |
| SHBG (nmol/L) category  |  |  |  |
| <20 | 5.42 | (2.32, 12.64) | <0.001 |
| 20 - 29.99 | 4.85 | (2.22, 10.58) | <0.001 |
| 30 - 39.99 | 1.76 | (0.73, 4.26) | 0.210 |
| 40 - 49.99 | 1.71 | (0.67, 4.35) | 0.259 |
| 50 - 59.99 | 0.98 | (0.30, 2.21) | 0.977 |
| ≥ 60 | 1.00 |  |
|  |  |  |  |

\*Patients without a known diagnosis of PCOS who had serum SHBG measurements. A limitation of these data is that many of these women with serum SHBG measurements may have had suspected androgen excess, and hence PCOS, despite the fact that this was not coded.